August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

pill bottles An analysis published in International Clinical Psychopharmacology found that paliperidone palmitate once-monthly (PP1M) had a more favorable benefit-risk profile compared to oral ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

Janssen announced today that the Scottish Medicines Consortium (SMC) has accepted paliperidone palmitate (Trevicta ®) for use within NHS Scotland. Paliperidone palmitate (Trevicta ®), a 3-monthly ...

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI ® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson's pharma unit Janssen is trumpeting a new version of its Invega drug that could solve ...

TITUSVILLE, N.J., May 19, 2015 / PR Newswire / — There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only schizophrenia medication to ...

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication Click-to-Tweet: #BREAKINGNEWS the @US_FDA approved new long-acting injectable treatment ...

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson's pharma unit Janssen is trumpeting a new version of its Invega drug that could solve ...